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OBJECTIVES: Little is known about the use and effectiveness of new treatments for
metastatic renal cell carcinoma (mRCC) in daily practice. In the Netherlands, this
information is needed for expensive inpatient drugs to guarantee continued reim-
bursement. We evaluated the use and effectiveness of bevacizumab plus interferon
alfa-2a (IFN) for patients with mRCC in Dutch daily practice. METHODS: A popula-
tion-based registry was created to include patients newly diagnosed with mRCC
from 2008-2010. These patients represent 55% of all patients in the Netherlands.
Data were collected on patient and disease characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. RESULTS: To date,
data on 615 patients have been collected. Average age at diagnosis was 66.4 years
(range: 23-93) and 66% was male. 53% of these patients received systemic therapy.
The majority (83%) was treated with sunitinib, whereas sorafenib is most often
used as second-line treatment. Data from 34 patients treated with bevacizumab
plus IFN in the first line were collected. The dosage corresponded with the recom-
mended dosage (10 mg/kg). Since the mean weight of patients in daily practice was
higher than the mean weight seen in the phase III trial (87.5 vs 76.0 kg), the mean
dosage was also higher. Of the 34 patients treated with bevacizumab plus IFN,
median overall survival was similar to that seen in the phase III trial (23.0 vs 23.3
months).CONCLUSIONS: Feasibility issues come into play when evaluating the use
and effectiveness of expensive inpatient drugs in daily practice. Since bevaci-
zumab plus IFN is not regularly used in daily practice, future cost-effectiveness
analyses will have to be based on a careful synthesis of evidence from daily prac-
tice, the phase III trial, quality of life studies and other sources.
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OBJECTIVES: Clinical studies typically assess average treatment effect on out-
comes, potentially ignoring heterogeneity of treatment effect associated with phe-
notypic and genotypic characteristics. A paradigm shift where drugs are targeted to
disease subtypes based on molecular biomarkers, rather than phenotypic or histo-
logical characteristics alone, is underway and beginning to influence outcomes
research. Our objective was to assess heterogeneity of treatment effect associated
with adjuvant and advanced-stage therapy for OC and strength of evidence docu-
menting association between patient or tumor characteristics and outcomes.
METHODS: We conducted a review according to the Cochrane Handbook of Sys-
tematic Reviews, with two independent reviewers completing study selection from
11 databases and data extraction on several outcomes: overall survival (OS), pro-
gression-free survival (PFS), tumor response, disease-free survival, time to progres-
sion, adverse events, and quality of life (QOL). Studies that did not evaluate char-
acteristics identified as predictive of anti-cancer treatment outcome, regardless of
whether treatment was molecularly targeted, were excluded. Descriptive analyses
were conducted. RESULTS: Forty-seven of 554 publications were selected (93%
concordance between reviewers). Most studies presented post-hoc analyses (45/
47); over half evaluated platinum-taxane combinations (27/47). Fifty-three distinct
patient or tumor characteristics were evaluated for association with outcomes.
Nine of the 10 most frequently studied characteristics were molecular: p53, VEGF,
ERCC1, CA-125, CD31-MVD, stathmin, TSP1-1A, III-tubulin and CD24. No studies
assessed predictive factors for QOL. Elevated CA-125 and stathmin levels were each
predictive of worsening OS and PFS, and VEGF levels or genotype were mostly
unrelated to OS or PFS. CONCLUSIONS: There are numerous studies that associate
mostly molecular markers with traditional measures of treatment effect; however,
patient-centered outcomes in this context have not yet been studied in OC. Future
evaluations of treatment effect in OC should also consider variation in these pa-
tient and tumor characteristics, in addition to histological and phenotypic charac-
teristics, for association with QOL.
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OBJECTIVES:To compare overall survival (OS) and progression free survival (PFS) in
sunitinib-refractory (SU-r) patients with mRCC treated with AXI and BSC using STC.
METHODS: STC method was used to derive OS and PFS curves for a hypothetical
cohort of “AXI-like” patients had they received BSC in the AXIS trial. Patient level
data on SU-r patients from the AXIS trial were used to derive predictive equations
for OS and PFS. Parametric survival analysis identified the best fitting distribution
and significant predictors of OS and PFS. These equations were calibrated using
patient characteristics and mPFS and cross-over adjusted mOS of the BSC cohort in
the RECORD-1 trial. RESULTS: In AXIS all 194 SU-r AXI patients progressed on one
line of treatment. In RECORD-1 78% of BSC patients had 2 prior lines and some
failed 1st line treatment due to intolerability. Other available patient characteristics
were comparable except for MSKCC risk category (36% vs 15% poor risk, AXI vs BSC
respectively) and ECOG score (52% vs 68% with ECOG 0). The final predictive equa-
tions using the best-fitting log-normal distribution included MSKCC risk group and
age for PFS, and MSKCC risk category and duration of prior SU for OS. Median
estimated OS and PFS was 15.2 and 5.1 months for AXI compared to 8.3 and 1.6
months for BSC respectively. Estimated difference in mean OS and PFS between
AXI and BSC was 11.4 and 5.9 months. Sensitivity analyses using patient charac-
teristics of the SU-r subgroup of everolimus arm and Weibull distribution showed
similar results. CONCLUSIONS: The STC analysis, an alternative to mixed treat-
ment comparison, suggested a significant improvement in OS and PFS for SU-r
mRCC patients treated with AXI compared to BSC. However, the analysis could not
account for all the differences between patient populations, particularly for the
number of prior non-VEGFR-TKI therapies.
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OBJECTIVES: With increasing health care resource constraints, it is important to
understand the incremental cost-effectiveness (ICER) of new medicines, and an
integral effort is to predict key clinical and economic outcomes over the patients’
lifetime. Our objective was to predict the lifetime mean overall survival (OS) and
bone metastasis-free survival (BMFS) for denosumab (120mg subcutaneous every 4
weeks) vs. placebo in men with CRPC based on a recent phase III trial (ClinicalTri-
als.gov NCT00286091).METHODS: A three-state health state model (BMFS, BM pro-
gression, and Death) was developed. Parametric survival functions for OS and
BMFS were estimated using trial data and extrapolated for lifetime. Model selection
was based on the best fit within trial duration (AIC criteria), and overall shape of the
lifetime predictions. For the parametric estimation, consistent with trial results,
pooled data from both study arms were used for OS; the placebo arm was used for
the baseline BMFS and the trial reported treatment effect (HR) was applied to derive
the BMFS curve for denosumab. RESULTS: A Weibull function was identified as the
best fit for both OS and BMFS. The pooled mean estimate was 4.02 years for OS, and
2.75 and 3.16 years for BMFS in placebo and denosumab respectively, resulting in
an incremental BMFS of 0.41 year for denosumab vs placebo. CONCLUSIONS: De-
nosumab treatment is predicted to prolong time in BMFS, which will reduce time in
BM progression state with potentially lower costs and costs offsets for denosumab
from reduced need of routine care in the metastatic health state. This finding will
facilitate our understanding of the ICER of denosumab in men with CRPC at high
risk of developing BM.
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OBJECTIVES: Chemotherapy-induced nausea and vomiting (CINV) is a significant
adverse effect of cancer chemotherapy treatment. The 5-hydroxytryptamine-3 re-
ceptor antagonists (5-HT3-RAs), a class of antiemetics, is indicated for the preven-
tion and treatment of CINV. The purpose of this study was to examine the use of
rescue antiemetic administration for CINV in patients diagnosed with cancer and
undergoing single-day chemotherapy. METHODS: A retrospective cohort analysis
using the Ingenix LabRx® database was conducted. Adult patients diagnosed with
lung, breast, or colon cancer, treated with a moderately (MEC) or highly emetogenic
chemotherapy (HEC), and who received a prophylactic 5-HT3-RA from 4/1/08 to
3/31/09, were identified. The outcome of interest was the rate of rescue antiemetic
administration, per cycle of chemotherapy, between 5-HT3-RA treatment cohorts.
Rescue antiemetic utilization was defined by a HCPCS code for administration of an
antiemetic from day 2 to the end of the cycle or for 30 days following single-day
chemotherapy. RESULTS A total of 5,912 patients were identified, 25.7% treated
with a HEC regimen and 74.3% on a MEC regimen.The mean age was 56.1 years and
77.1% were female. Patients were treated with a total of 21,821 cycles of chemo-
therapy. The most common 5-HT3-RA utilized was palonosetron (73% of cycles)
followed by ondansetron (11%), granisetron (10%), and dolasetron (6%). The overall
unadjusted rate of rescue antiemetic administration per cycle was 17.6%, and the
rate differed by 5-HT3-RA utilized. Patients treated with palonosetron were signif-
icantly less likely to require a rescue antiemetic on a per cycle basis (14.1%), com-
pared to patients treated with another 5-HT3-RA (26.6%), p.001. CONCLUSIONS:
The results from this retrospective analysis suggest that rescue antiemetic utiliza-
tion may be significantly reduced in patients undergoing chemotherapy following
use of palonosetron vs. another 5-HT3-RA for the prevention of CINV.
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OBJECTIVES: While persistence with drug therapy is essential to achieve optimal
patient benefits, poorly controlled MM results in earlier disease progression, dis-
ease-related complications, deleteriously impacts quality of life, and ultimately
death. This study assesses the relationship between treatment LEN adherence/
persistence and indicators of lack of disease control and disease-related complica-
tions of MM. METHODS: Commercial and Medicare Advantage enrollees initiating
LEN for treatment of MM with pharmacy and medical benefits in the 6 months prior
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